Structure of Raltitrexed
CAS No.: 112887-68-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Raltitrexed is an inhibitor of thymidylate synthase with IC50 of 9 nM in L1210 cell.
Synonyms: ZD1694; D1694; TDX
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 112887-68-0 |
Formula : | C21H22N4O6S |
M.W : | 458.49 |
SMILES Code : | O=C(O)[C@@H](NC(C1=CC=C(N(C)CC2=CC3=C(N=C(C)NC3=O)C=C2)S1)=O)CCC(O)=O |
Synonyms : |
ZD1694; D1694; TDX
|
MDL No. : | MFCD00864168 |
InChI Key : | IVTVGDXNLFLDRM-HNNXBMFYSA-N |
Pubchem ID : | 135400182 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
Kyse150 cells | 4 nM | 24 hours | To evaluate the inhibitory effect of Raltitrexed on Kyse150 cell proliferation and its radiosensitization effect. The results showed that Raltitrexed significantly enhanced the radiosensitivity of Kyse150 cells, increasing DNA double-strand breaks, G2/M arrest, and apoptosis. | PMC6378748 |
TE-13 cells | 4 nM | 24 hours | To evaluate the inhibitory effect of Raltitrexed on TE-13 cell proliferation and its radiosensitization effect. The results showed that Raltitrexed significantly enhanced the radiosensitivity of TE-13 cells, increasing DNA double-strand breaks, G2/M arrest, and apoptosis. | PMC6378748 |
LAN-1 | 54 ± 11 nM | 72 hours | To evaluate the growth inhibitory activity of Raltitrexed on MYCN-amplified neuroblastoma cells, the results showed that Raltitrexed had significant growth inhibitory effects on LAN-1 cells. | PMC7385364 |
LAN-5 | 25 ± 7.8 nM | 72 hours | To evaluate the growth inhibitory activity of Raltitrexed on MYCN-amplified neuroblastoma cells, the results showed that Raltitrexed had significant growth inhibitory effects on LAN-5 cells. | PMC7385364 |
NB-39 | 16 ± 3.2 nM | 72 hours | To evaluate the growth inhibitory activity of Raltitrexed on MYCN-amplified neuroblastoma cells, the results showed that Raltitrexed had significant growth inhibitory effects on NB-39 cells. | PMC7385364 |
KELLY | 8.9 ± 0.64 nM | 72 hours | To evaluate the growth inhibitory activity of Raltitrexed on MYCN-amplified neuroblastoma cells, the results showed that Raltitrexed had significant growth inhibitory effects on KELLY cells. | PMC7385364 |
SK-N-BE(2) | 6.1 ± 2.1 nM | 72 hours | To evaluate the growth inhibitory activity of Raltitrexed on MYCN-amplified neuroblastoma cells, the results showed that Raltitrexed had significant growth inhibitory effects on SK-N-BE(2) cells. | PMC7385364 |
IMR-32 | 5.7 ± 1.8 nM | 72 hours | To evaluate the growth inhibitory activity of Raltitrexed on MYCN-amplified neuroblastoma cells, the results showed that Raltitrexed had significant growth inhibitory effects on IMR-32 cells. | PMC7385364 |
COLO 205 | 0, 0.2, 2, 20, 200, 2000 μM | 90 minutes | Evaluate the synergistic effect of Raltitrexed under hyperthermia conditions, results showed Raltitrexed had the highest HCSER score under hyperthermia. | PMC8330527 |
DLD-1 | 0, 0.2, 2, 20, 200, 2000 μM | 90 minutes | Evaluate the synergistic effect of Raltitrexed under hyperthermia conditions, results showed Raltitrexed had the highest HCSER score under hyperthermia. | PMC8330527 |
SW480 | 0, 0.2, 2, 20, 200, 2000 μM | 90 minutes | Evaluate the synergistic effect of Raltitrexed under hyperthermia conditions, results showed Raltitrexed had a high HCSER score under hyperthermia. | PMC8330527 |
SW620 | 0, 0.2, 2, 20, 200, 2000 μM | 90 minutes | Evaluate the synergistic effect of Raltitrexed under hyperthermia conditions, results showed Raltitrexed had the highest HCSER score under hyperthermia. | PMC8330527 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Swine | Swine model | Hepatic arterial infusion | 1 mg/4 mg | Not specified | To study the pharmacokinetic characteristics of Raltitrexed in a swine model to determine the appropriate concentration and infusion time for hepatic arterial infusion chemotherapy. | PMC6010942 |
Caenorhabditis elegans | CL2006 transgenic worms | Treatment in liquid medium | 1-50 μM | Not specified | Raltitrexed significantly reduced H3K9me2 levels in CL2006 worms, enhanced locomotive function, and reduced Aβ aggregates by up to 47%. | PMC10641905 |
BALB/C nude mice | TE-13 xenograft model | Intraperitoneal injection | 7.5 mg/kg/day | Continuous for 5 days, followed by a 2-day interval and another 5 days | To evaluate the radiosensitization effect of Raltitrexed on TE-13 xenograft tumors. The results showed that Raltitrexed significantly enhanced the inhibitory effect of radiation on tumor growth, reducing tumor volume and weight, and decreasing the expression of Ki-67 and PCNA. | PMC6378748 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02678806 | HepatoCellular Carcinoma | Not Applicable | Recruiting | November 1, 2022 | China, Guangxi ... More >> TaoBai Recruiting Nanning, Guangxi, China, 530000 Contact: Bai Tao, MD +86 13878862632 25859373@qq.com Less << |
NCT01703910 | Adenocarcinoma of Colon ... More >> Adenocarcinoma of Rectum Metastatic Disease Less << | Phase 2 | Completed | - | Spain ... More >> Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain, 28950 Hospital Madrid Norte Sanchinarro Madrid, Spain, 28050 Less << |
NCT01481545 | Rectal Cancer | Phase 2 | Unknown | July 2018 | - |
NCT00797719 | Malignant Pleural Mesothelioma | Phase 1 Phase 2 | Recruiting | July 2019 | Canada, Ontario ... More >> University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: John Cho, MD 416 946 2124 john.cho@rmp.uhn.on.ca Principal Investigator: John Cho, MD Less << |
NCT03191487 | Colorectal Neoplasms | Not Applicable | Withdrawn(no Financial agreeme... More >>nt) Less << | November 2019 | France ... More >> Institut Sainte Catherine Avignon Cedex 9, France, 84918 Institut de Cancérologie Montpellier Montpellier Cedex 5, France, 34298 CHRU de Nîmes - Hôpital Universitaire Carémeau Nîmes, France, 30029 CHRU de Strasbourg - Hôpital de Hautepierre Strasbourg, France, 67098 CHRU de Toulouse - Hôpital de Rangueil Toulouse Cedex 9, France, 31059 IUCT-Oncopole Toulouse, France, 31100 Less << |
NCT01869023 | Advanced Malignant Pleural Mes... More >>othelioma Less << | Phase 2 | Active, not recruiting | December 2017 | Mexico ... More >> Instituto Nacional de Cancerología Mexico City, Mexico Less << |
NCT03179579 | Gastric Cancer ... More >> Peritoneal Carcinomatosis Less << | Phase 3 | Not yet recruiting | August 1, 2022 | China, Guangdong ... More >> Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University Not yet recruiting Guangzhou, Guangdong, China, 510095 Contact: Xianzi Yang, M.D 8602066673666 7097359@qq.com Principal Investigator: shuzhong cui, M.D Less << |
NCT02376452 | Colorectal Carcinoma | Phase 2 | Unknown | December 2016 | China, Shanghai ... More >> Fudan University Cancer Hospital Recruiting ShangHai, Shanghai, China Contact: Jin Li, PhD, M.D 862164175590 ext 1108 fudanlijin@163.com Less << |
NCT02723253 | Rectal Neoplasms | Phase 2 | Completed | - | - |
NCT00002902 | Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << | Phase 1 | Completed | - | United States, Pennsylvania ... More >> University of Pennsylvania Cancer Center Philadelphia, Pennsylvania, United States, 19104 Less << |
NCT00004254 | Malignant Mesothelioma | Phase 2 | Completed | - | Italy ... More >> Ospedale Bellaria Bologna, Italy, I-40139 Istituto Nazionale per la Ricerca sul Cancro Genoa, Italy, 16132 Istituto Nazionale per lo Studio e la Cura dei Tumori Naples, Italy, 80131 Universita Degli Studi di Udine Udine, Italy, 33100 Netherlands Antoni van Leeuwenhoekhuis Amsterdam, Netherlands, 1066 CX Vrije Universiteit Medisch Centrum Amsterdam, Netherlands, 1117 MB Less << |
NCT00003109 | Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << | Phase 1 | Completed | - | United States, Pennsylvania ... More >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less << |
NCT01532804 | Metastatic Colorectal Cancer | Phase 2 | Active, not recruiting | December 2018 | France ... More >> Val d'Aurelle Cancer Institute Montpellier, France, 34298 Less << |
NCT00002828 | Colorectal Cancer | Phase 1 | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less << |
NCT00001341 | Neoplasm | Phase 1 | Completed | - | United States, Maryland ... More >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Less << |
NCT00004920 | Malignant Mesothelioma | Phase 3 | Completed | - | - |
NCT02965248 | Locally Advanced Colorectal Ca... More >>ncer Less << | Phase 3 | Recruiting | November 2023 | China, Shanghai ... More >> Fudan University Shanghai Cancer Center Recruiting Shanghai, Shanghai, China, 200032 Contact: Guoxiang Cai, M.D. Ph.D. +86 13611831623 gxcai@fudan.edu.cn Less << |
NCT02453490 | Colorectal Cancer ... More >> Liver Metastasis Less << | Phase 3 | Recruiting | September 2018 | China, Guangdong ... More >> The Affiliated Tumor Hospital of Zhongshan University Not yet recruiting Guangzhou, Guangdong, China, 510060 Principal Investigator: Zhi-Zhong Pan, MD/PHD China, Hubei Wuhan Union Hospital Not yet recruiting Wuhan, Hubei, China, 430022 Principal Investigator: Kai-Xiong Tao, MD/PHD Zhongnan Hospital Affiliated to Wuhan University Not yet recruiting Wuhan, Hubei, China, 430071 Principal Investigator: Bing Xiong, MD China, Shanghai Changhai Hospital of Shanghai Recruiting Shanghai, Shanghai, China, 200433 Principal Investigator: Wei Zhang, MD China, Zhejiang The First Affiliated Hospital of College of Medicine Zhejiang University Not yet recruiting Hangzhou, Zhejiang, China, 310003 Principal Investigator: Jianjiang Lin, M.D. Second Affiliated Hospitalof Zhejiang University School of Medicine Recruiting Hangzhou, Zhejiang, China, 310009 Contact: Ke-Feng Ding, PhD/MD 86-571-87784827 dingkefeng@zju.edu.cn Principal Investigator: Ke-Feng Ding, PhD/MD Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Recruiting Hangzhou, Zhejiang, China, 310016 Principal Investigator: Xuefeng Huang, M.D. Jinhua People's Hospital Recruiting Jinhua, Zhejiang, China, 321000 Principal Investigator: Jinlin Du, M.D. The second hospital of Ningbo City Recruiting Ningbo, Zhejiang, China, 315010 Principal Investigator: Xiao-Yu Dai, MD Less << |
NCT02631564 | - | Unknown | December 2018 | China, Shanghai ... More >> Fudan University Zhongshan Hospital Recruiting Shanghai, Shanghai, China, 200032 Contact: Bo Zhou, M.D,Ph.D 8621-18616880602 Less << | |
NCT00590278 | Inoperable or Recurrent Rectal... More >> Cancer Less << | Phase 2 | Completed | - | Turkey ... More >> Research Site Istanbul, Turkey Less << |
NCT00234429 | Colorectal Cancer | Phase 2 Phase 3 | Completed | - | Spain ... More >> Research Site A Coruna, Spain Research Site Barcelona, Spain Research Site Burgos, Spain Research Site Gijon, Spain Research Site Leon, Spain Research Site Madrid, Spain Research Site Oviedo, Spain Research Site Pamplona, Spain Research Site Valladolid, Spain Less << |
NCT02821559 | Metastatic Colorectal Cancer | Phase 2 | Completed | - | France ... More >> CHRU de Besançon Besançon, France Less << |
NCT00003528 | Recurrent Childhood Acute Lymp... More >>hoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Less << | Phase 1 | Completed | - | Switzerland ... More >> Swiss Pediatric Oncology Group - Geneva Geneva, Switzerland, 1205 Less << |
NCT02485548 | Head and Neck Squamous Cell Ca... More >>ncer Less << | Phase 3 | Unknown | June 2018 | China, Jiangsu ... More >> Jiangsu Cancer Hospital Recruiting Nanjing, Jiangsu, China, 210009 Contact: Xuesong Jiang, M.D. 13851700790@126.com Sub-Investigator: Xuesong Jiang, M.D. Less << |
NCT01959061 | Colorectal Cancer Metastatic | Phase 4 | Recruiting | December 2017 | China, Shanghai ... More >> Zhongshan Hospital Fudan University Recruiting Shanghai, Shanghai, China, 2000032 Contact: Jianhua Wang Less << |
NCT02992886 | Rectal Neoplasms Malignant | Phase 2 | Recruiting | September 2022 | China, Beijing ... More >> Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Recruiting Beijing, Beijing, China, 100021 Contact: Wenyang Liu, MD liuwenyang26@163.com Less << |
NCT01732380 | Inoperable Esophageal Cancer S... More >>tage I-III Less << | Phase 2 | Unknown | July 2013 | China, Jiangsu ... More >> The First People`s Hospital of Lianyungang Recruiting Lianyungang, Jiangsu, China, 222002 Contact: Xiaodong Jiang, Doctor jxdysy1970@163.com Less << |
NCT03126071 | Advanced Colorectal Cancer | Phase 2 | Recruiting | February 15, 2020 | China, Jiangsu ... More >> Jiangsu Cancer Institute & Hospital Recruiting Nanjing, Jiangsu, China, 210009 Contact: Liangjun Zhu +8613905199123 zhulj98@foxmail.com Contact: Yuejiao Zhong +861370575447 zhongyuejiao@163.com Nantong Tumor Hospital Active, not recruiting Nantong, Jiangsu, China, 226000 The First Affiliated Hospital of Soochow University Recruiting Suzhou, Jiangsu, China, 215000 Contact: Chunrong Zhu, M.D. +8613063870566 zcr050311@163.com Contact: Feng Xiong +8613270971002 greenlemontea@126.com China, Shanghai Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Not yet recruiting Shanghai, Shanghai, China, 200025 Contact: Jun Zhang, M.D. Less << |
NCT01836120 | Gastric Cancer | Phase 2 | Unknown | June 2017 | China, Hebei ... More >> Hebei Tumor Hospital Shijiazhuang, Hebei, China, 050011 Less << |
NCT02072317 | Advanced Gastric Cancer | Phase 2 | Unknown | March 2016 | China, Shanghai ... More >> Cancer hospital Fudan University Recruiting Shanghai, Shanghai, China, 200032 Contact: GUO WEI JIAN, doctor 13816066360 guoweijian1@hotmail.com Less << |
NCT00002893 | Colorectal Cancer | Phase 3 | Unknown | - | United Kingdom ... More >> Velindre Hospital Cardiff, Wales, United Kingdom, CF4 7XL Less << |
NCT03585530 | Esophagus Squamous Cell Carcin... More >>oma Less << | Phase 2 | Not yet recruiting | July 15, 2022 | - |
NCT03083613 | Gastric Cancer ... More >> Gastroesophageal Junction Adenocarcinoma Less << | Phase 2 | Unknown | December 2018 | China ... More >> Chinese Academy of Medical Sciences Recruiting Beijing, China, 10000 Contact: Ai ping Zhou 8610-87788145 zhouap1825@126.com Less << |
NCT03053167 | ColoRectal Cancer | Phase 2 | Recruiting | December 2020 | China, Liaoning ... More >> The First Hospital of China Medical University Recruiting Shenyang, Liaoning, China, 110001 Contact: Yunpeng Liu, MD., PhD 86-24-83282312 cmuliuyunpeng@hotmail.com Principal Investigator: Yunpeng Liu, MD., PhD. Less << |
NCT03398512 | Peritoneal Metastases From Col... More >>orectal Cancer Less << | Not Applicable | Recruiting | December 31, 2020 | China, Hubei ... More >> Wuhan University Recruiting Wuhan, Hubei, China Contact: Bin Xiong +86 27 67813152 jyn1983@163.com Less << |
NCT02562599 | Nasopharyngeal Carcinoma | Phase 2 | Unknown | August 2018 | China, Hubei ... More >> Hubei Cancer hospital Recruiting Wu Han, Hubei, China, 430079 Contact: Han Guang, PH.D Principal Investigator: Hu Desheng, M.D Less << |
NCT02618356 | Metastatic Colon Cancer | Phase 2 | Recruiting | November 2017 | China, Shanghai ... More >> Fudan University Cancer Hospital Recruiting ShangHai, Shanghai, China, 200032 Contact: Wei Jian Guo 13816066360 mingzhuhuang0718@163.com Less << |
NCT03344614 | Colorectal Cancer | Phase 2 | Recruiting | July 1, 2019 | China, Beijing ... More >> Chinese PLA General Hospital (301 Military Hospital) Recruiting Beijing, Beijing, China, 100853 Contact: Haiyan Si, M.D. +8613911070673 sihaiyan2008@sina.com Less << |
NCT03196843 | Head and Neck Squamous Cell Ca... More >>rcinoma Less << | Phase 4 | Recruiting | August 2022 | China, Liaoning ... More >> Lv Xiupeng Recruiting Dalian, Liaoning, China, 116000 Contact: Xiupeng Lv, M.D. 18098876707 lvxiupeng@foxmail.com Less << |
NCT01348412 | Colorectal Cancer ... More >> Liver Metastases Less << | Phase 2 | Completed | - | France ... More >> Centre Georges François Leclerc Dijon, France, 21000 Less << |
NCT03392103 | Gastric Cancer | Phase 2 | Recruiting | December 2019 | China, Hubei ... More >> Zhongnan Hopital of Wuhan University Recruiting Wuhan, Hubei, China, 430071 Contact: Fuxiang Zhou, M.D. +86(0)2767813155 fuxiang.zhou@whu.edu.cn Contact: Jing Dai, M.D. +86(0)2767813155 daijing1116@163.com Less << |
NCT02557490 | Colon Cancer Liver Metastasis | Phase 4 | Unknown | December 2017 | China, Beijing ... More >> Beijing Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Zhu Xu, Master 0086-10-88195476 zhux387@263.net Principal Investigator: Zhu Xu, Master Less << |
NCT04761185 | Colorectal Cancer|Raltitrexed|... More >>HIPEC Less << | PHASE1 | UNKNOWN | 2022-12-31 | Fudan University Shanghai Canc... More >>er Center, Shanghai, 200032, China Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.91mL 2.18mL 1.09mL |
21.81mL 4.36mL 2.18mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|